HK Stock Market Move | TRIP.COM-S (09961) is currently down by more than 4%, travel to Japan is cooling off, Ctrip stated that they are assisting customers to cancel hotel bookings.
Ctrip Group-S (09961) fell more than 6% in early trading, as of press time, it fell by 4.17% to HKD 552.5, with a turnover of HKD 1.316 billion.
Trip.com-S (09961) fell more than 6% in early trading, down 4.17% as of the close of the market at 552.5 Hong Kong dollars, with a turnover of 13.16 billion Hong Kong dollars.
On the news front, on November 14, the Ministry of Foreign Affairs and the Chinese Embassy in Japan solemnly reminded Chinese citizens to avoid traveling to Japan recently. On November 16, Red Star News called Trip.com, and customer service said the platform is also closely monitoring. Many hotel orders in Japan are being canceled, and Trip.com is helping customers with this; some customers are still observing. Some hotels are easy to communicate with, agreeing to free changes and cancellations, Trip.com can submit applications directly and process refunds automatically; while some hotels require further communication and are still being coordinated.
Goldman Sachs previously released a research report stating that Trip.com Group's outbound travel business growth is normalizing, with a year-on-year growth of 14-15%, slightly better than the company's guidance of 10-20% at the lower end. Credit Suisse also stated that, benefiting from economies of scale in research and development and management expenses, Trip.com's overall adjusted profit margin is still clearly on an upward trend. With further improvement in Trip.com's profitability, it is expected that the profit margin will increase.
Related Articles

Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-4642 Injection and other drugs have received clinical trial approval.

CMSC International: Raises target price of TENCENT (00700) to HKD 766, maintains "buy" rating.

Sichuan Teway Food Group's (603317.SH) application materials for the issuance of H shares have been accepted by the China Securities Regulatory Commission.
Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-4642 Injection and other drugs have received clinical trial approval.

CMSC International: Raises target price of TENCENT (00700) to HKD 766, maintains "buy" rating.

Sichuan Teway Food Group's (603317.SH) application materials for the issuance of H shares have been accepted by the China Securities Regulatory Commission.

RECOMMEND

Energy Storage Industry Set To Ride the AI Tailwind; UBS: Global Demand May Surge 40% Next Year
13/11/2025

Double Eleven’s Cooling To A Historic Low? A Necessary Step Toward E‑commerce Maturity
13/11/2025

On The Eve of L3 Mass Commercialization: How Autonomous Driving Will Reconfigure a Trillion‑Yuan Service Market
13/11/2025


